Royalty Pharma RPRX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | —— | —— | —— | ||
| $2.61B-3.3% | $2.49B-10.1% | $2.41B-14.1% | $2.41B-9.8% | $2.7B+3.1% | ||
| $12.96M-58.1% | $21.23M+7.3% | $30.93M+258% | $30.93M+437% | $30.93M+974% | ||
| $2.15B-11.2% | $1.7B-32.2% | $1.46B-51.5% | $1.69B-25.3% | $2.42B+51.3% | ||
| -$2.6B-24.4% | -$1.61B+39.7% | -$1.27B+59.9% | -$1.51B+38.0% | -$2.09B-30.4% | ||
| $568.7M-39.4% | $1.23B+434% | $1.2B+479% | $1.15B+359% | $938.43M— | ||
| $153.52M+4.5% | $167.48M+33.8% | $158.17M+33.8% | $154.9M+30.9% | $146.98M+24.4% | ||
| -$2.02M— | -$1.79M— | -$1K— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$501.33M— | -$310.33M— | —— | —— | —— | ||
| $311M+41.7% | $276.29M+73.1% | $270.42M+66.8% | $219.42M+32.4% | $219.42M+32.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $20.64M— | $10.94M— | $1.87M— | $173K— | —— | ||
| $222.69M-19.7% | $288.14M+22.0% | $302.32M+38.7% | $323.37M+48.5% | $277.4M+28.0% | ||
| $115.88M+1.4% | $114.02M+4.8% | $114.43M-25.6% | $115.13M-22.6% | $114.29M-30.9% | ||
| $3.44B+12.1% | $3.35B+12.4% | $3.22B+8.9% | $3.13B+8.9% | $3.07B+9.8% | ||
| $4.32M+237% | $720K-95.1% | $908K-93.8% | $1.03M-92.9% | $1.28M-91.0% | ||
| $271.31M+117% | $271.31M+262% | $293.6M— | $293.6M— | $125M— | ||
| —— | —— | —— | —— | $66.93M— | ||
| $35.1M-52.5% | $34.72M-64.8% | $24.64M-66.7% | $49.29M0.0% | $73.93M+200% | ||
| —— | —— | —— | —— | $510.55M— | ||
| $12.96M-58.1% | $21.23M+7.3% | $30.93M+258% | $30.93M+437% | $30.93M+974% | ||
| —— | $0— | $0-100% | $0-100% | $0-100% | ||
| $387.39M+2.5% | $378.25M+0.5% | $377.57M+1.5% | $376.32M+2.3% | $378.02M+4.0% | ||
| $153.52M+4.5% | $167.48M+33.8% | $158.17M+33.8% | $154.9M+30.9% | $146.98M+24.4% | ||
| $348.25M-3.1% | $354.9M-2.0% | $356.95M-4.4% | $356.6M-4.2% | $359.3M— | ||
| $4.62M+12.7% | $5.7M+30.7% | $6.73M+54.8% | $7.75M+56.2% | $4.1M-17.3% | ||
| —— | —— | —— | $878K+81.4% | $879K+150% | ||
| -$2.02M— | -$1.79M— | -$1K— | —— | —— | ||
| $28.78M-44.7% | $34.31M-26.2% | $36.97M-19.5% | $46.26M-20.3% | $52.08M-16.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Royalty Pharma generate?
- Royalty Pharma (RPRX) generated $2.6B in operating cash flow over the trailing twelve months.
- Where does Royalty Pharma's cash flow data come from?
- Every line is extracted from Royalty Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
